It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
It was the third trigger of the recession indicator in less than two weeks.Bondsread more
Overstock CEO Partick Byrne has resigned from the e-commerce company after making comments about his role in the "deep state."Technologyread more
Automakers are trying to deal with President Trump's efforts to roll back Obama-era fuel efficiency rules.Autosread more
Mark Zuckerberg has been on a selling spree in August and has unloaded $526 million worth of stock this year.Technologyread more
Palantir CEO Alex Karp said billionaire investor Peter Thiel is right to question Google's decision to work in China, while abandoning military contracts in the US.Technologyread more
These are the stocks posting the largest moves midday.Market Insiderread more
U.S. manufacturer growth slowed to the lowest level in almost 10 years in August, the latest sign that the trade war may be exacerbating the economic slowdown.Marketsread more
L Brands shares fell by as much as 12% at one point, touching $17.61 — a price not seen since December 2009.Retailread more
"The president is not backing down," says CNBC's Jim Cramer, referring to Trump's repeated calls for the Fed to cut rates while talking tough on China.Economyread more
The market rebound this week hasn't convinced the strategist predicting a "Lehman-like" sell-off that the risk is completely off the table.Marketsread more
(Adds statement from Biogen)
NEW YORK, May 14 (Reuters) - England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.
NHS England said it reached a "managed access agreement" with Biogen under which it will fund treatment for a limited time and collect data on the drug's effectiveness.
NHS England did not disclose the price it will pay for the drug.
Biogen confirmed the deal on Tuesday and said it applauded the decision by the National Institute for Health and Care Excellence to recommend funding for Spinraza in the United Kingdom.
Spinraza, which is administered by spinal injection every four months, has a U.S. list price of $750,000 for the first year and $375,000 annually thereafter.
Britain's healthcare cost agency, NICE, said in August it could not recommend Spinraza as a cost effective treatment. The rejection came despite a lower British price tag of 450,000 pounds ($573,000) for the first year and Biogen offering an undisclosed discount to the National Health Service.
Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality, affecting one in every 10,000 live births. About 60 percent of patients have the most severe Type 1 form of the disease, which often leads to paralysis, impaired breathing and death by the second birthday.
Between 600 and 1,200 children and adults are currently living with the condition in England and Wales, according to NHS England. Spinraza will be made available immediately to Type 1 patients by Biogen, it said.
It said that Spinraza will be made available for other patients - including adults and siblings who have yet to show symptoms - in a few weeks, after NICE publishes guidance.
Spinraza was the first approved treatment for SMA, but is expected to soon face new competition. The U.S. Food and Drug Administration is due to decide on approval for Novartis' gene therapy Zolgensma this month, with other regulators expected to follow suit later this year.
Novartis says the one-time treatment could be a cure for SMA and is pushing for a price in the range of $1.5 million to $5 million. That would make Zolgensma the most expensive new therapy. (Reporting by Michael Erman; Additional reporting by Caroline Humer and Rishika Chatterjee; editing by Bill Berkrot)